ESG206

· Shanghai Escugen Biotechnology Co., Ltd

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for ESG206, covering 2025-05-16 to 2026-02-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome [Phase 2]

See pricing